BridgeBio Reports Strong Q1 2026 Revenue Growth on Attruby Momentum
Event summary
- BridgeBio reported $194.5 million in Q1 2026 revenue, driven by $180.6 million in U.S. Attruby net product revenue.
- Attruby demonstrated a 43% reduction in diuretic intensification compared to tafamidis in real-world evidence.
- BridgeBio submitted its first NDA for BBP-418 in LGMD2I/R9, with two more NDAs planned for encaleret and infigratinib in 2026.
- The company has $940.2 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
- BridgeBio's Board authorized a $500 million share repurchase program.
The big picture
BridgeBio's Q1 2026 results highlight the continued commercial success of Attruby, reinforcing its position as a key player in the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). The company's strategic focus on filing and launching three new therapies within the next year positions it for significant growth, though it must navigate regulatory hurdles and maintain its strong financial footing. The share repurchase program signals confidence in the company's valuation and provides flexibility for future investments.
What we're watching
- Regulatory Milestones
- The pace at which BridgeBio secures FDA approvals for BBP-418, encaleret, and infigratinib will determine the timing of its next commercial launches.
- Commercial Execution
- Whether BridgeBio can sustain Attruby's strong prescribing growth and patient persistence while preparing for three critical launches in the next 12 months.
- Financial Strategy
- How BridgeBio's $500 million share repurchase program will impact its cash position and investor perception of its intrinsic value.
Related topics